Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line intermittent docetaxel and estramustine for hormone-refractory prostate cancer
2006-005728-17Phase 2Active
- Sponsor
- Azienda Provinciale per i Servizi Sanitari
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and estramustine in castration-resistant prostate cancer (CRPC), sponsored by Azienda Provinciale per i Servizi Sanitari. Primary endpoints: Change in global health status quality of life and Biochemical progression-free rate. Started Jan 2007; status: active.
02
Drugs
docetaxelestramustine
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2006-005728-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005728-17.